Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study

Mellar Davis, Charles Loprinzi

Research output: Contribution to journalReview articlepeer-review

Abstract

Chemotherapy-induced neuropathy is difficult to manage, and the pain associated with neuropathy is poorly responsive to gabapentin in a randomized trial. Duloxetine is the only drug that has been found to be effective in reducing pain from chemotherapy neuropathy. In this qualitative review, the use of pregabalin for chemotherapy-induced neuropathy is discussed including the rationale and pharmacological reasons why pregabalin should be considered in a large, randomized placebo-controlled trial.

Original languageEnglish (US)
Pages (from-to)8845-8853
Number of pages9
JournalSupportive Care in Cancer
Volume30
Issue number11
DOIs
StatePublished - Nov 2022

Keywords

  • Alpha2dellta
  • Calcium channel
  • Chemotherapy
  • Neuropathy
  • Pain
  • Pregabalin

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study'. Together they form a unique fingerprint.

Cite this